Form 4: Neuronetics CFO Awarded 25,000 Restricted Stock Units

Neuronetics, Inc.'s EVP, CFO, and Treasurer, Steven Pfanstiel, was granted 25,000 restricted stock units vesting over three years.

Summary

• Steven Pfanstiel, Executive Vice President, Chief Financial Officer, and Treasurer of Neuronetics, Inc., acquired 25,000 restricted stock units (RSUs).
• The RSUs were granted on March 17, 2026, at a price of $0, as each RSU represents a contingent right to receive one share of the Issuer's common stock.
• These RSUs will vest in three equal annual installments, with the first installment commencing on March 17, 2027, contingent upon Mr. Pfanstiel's continuous service.
• Following this transaction, Mr. Pfanstiel directly beneficially owns 845,212 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting standard executive incentive alignment and retention efforts, which are generally favorable for long-term stability.

Positives

• The grant of 25,000 restricted stock units to a key executive like the EVP, CFO, and Treasurer aligns management's interests with long-term shareholder value.
• The three-year vesting schedule encourages executive retention and sustained performance, contributing to company stability.

Negatives

• There is no immediate cash inflow for the executive, as these are restricted stock units that vest over time and are subject to continuous service.

Risks

• The vesting of the restricted stock units is contingent upon the reporting person's continuous service, meaning forfeiture if employment ceases before the specified vesting dates.

Future Outlook

The grant of long-term equity incentives suggests an expectation of continued executive tenure and performance, which is anticipated to contribute to the company's future growth and strategic objectives.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units with multi-year vesting, are a standard practice in the medical device and technology sectors to incentivize and retain key executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) with a multi-year vesting schedule is a common compensation practice for executive retention in the biotechnology and medical technology industries, comparable to practices at companies like Medtronic or Boston Scientific.
• The grant size of 25,000 units for a CFO is within typical ranges for a company of Neuronetics' size, aiming to provide significant long-term incentive without excessive dilution.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential long-term benefit from executive retention and performance alignment; minor future dilution upon vesting.
• Employees: May signal stability in executive leadership and a commitment to long-term incentive programs.

Next Steps

• Continued service of Steven Pfanstiel to ensure the vesting of the restricted stock units.
• Future annual vesting events for the RSUs on March 17, 2027, and subsequent years.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, which is a standard practice for executive compensation and retention. It does not present new information that would fundamentally alter the company's financial outlook or strategic direction to warrant a change in investment recommendation. It primarily reinforces management's long-term alignment with shareholder interests, supporting a 'hold' position for existing investors.

Keywords

Neuronetics, STIM, Steven Pfanstiel, Restricted Stock Units, RSU, Insider Trading, Form 4, Executive Compensation, Equity Grant, Corporate Governance